Sara Manglaviti

5PUBLICATIONS
34CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 16, 2024
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.

Rita Leporati, Daniela Miliziano, Teresa Beninato

|Apr 12, 2023
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.

Luca Cantini, Francesco Paoloni, Federica Pecci

|Sep 01, 2022
Is hyperprogressive disease a specific phenomenom of immunotherapy?

Marta Brambilla, Giuseppe Lo Russo, Roberto Ferrara

|Jun 02, 2021
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors.

Mario Occhipinti, Marta Brambilla, Giulia Galli

|Jun 13, 2020
Comparison of outcomes of central venous catheters in patients with solid and hematologic neoplasms: an Italian real-world analysis.

Francesca Corti, Marta Brambilla, Sara Manglaviti

Pageof 1

Frequent Collaborators

3 joint publications

Mario Occhipinti

2 joint publications

Marta Brambilla

1 joint publications

Francesca Corti

1 joint publications

Arsela Prelaj